Thetis Pharmaceuticals LLC — SEC Form D Filing
Thetis Pharmaceuticals LLC filed an SEC Form D on October 13, 2026, reporting $560K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 13, 2026
- Amount reported
- $560K
- Round stage
- Series B+
- Industry
- Biotechnology
- Website
- https://www.thetispharma.com/
What the company does
Securities: Debt. Exemption: Rule 506(b). Incorporated: CONNECTICUT
Problem
The company addresses inflammatory bowel disease (IBD), specifically moderate-to-severe ulcerative colitis, and solid tumors.
Solution
Thetis Pharmaceuticals is developing TP-317, an oral Resolvin E1 (RvE1) drug that activates BLT1 to restore and maintain tissue and immune homeostasis.
Verdict
This cleared because the drug's mechanism offered a novel approach to highly prevalent inflammatory diseases, appealing to investors seeking pipeline diversification in an established therapeutic area. Investors were implicitly betting on early-stage clinical differentiation based on a potentially superior safety and efficacy profile, not on a proven market-entry strategy. This limited upside by anchoring the valuation to clinical milestones rather than rapid commercial scaling, contrasting with platform plays that offer broader applicability.
Source: SEC EDGAR Form D filing